Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 2,718,346,000, representing a 2.2% increase from RMB 2,658,973,000 in 2024[3] - Gross profit decreased by 12.0% to RMB 424,066,000 from RMB 482,042,000 in the previous year[3] - Net profit attributable to equity shareholders for the year was RMB 94,936,000, down 12.8% from RMB 108,922,000 in 2024[3] - Basic and diluted earnings per share decreased by 13.6% to RMB 0.38 from RMB 0.44 in 2024[3] - Operating profit for the year was RMB 164,021,000, a decrease from RMB 194,537,000 in the previous year[4] - The net profit before tax decreased to RMB 140,343,000 in 2025 from RMB 168,034,000 in 2024, a decline of 16.5%[27] - Profit for the period decreased from RMB 108.9 million to RMB 94.9 million, with the net profit margin dropping from 4.1% to 3.5%[51] Assets and Liabilities - Non-current assets increased to RMB 2,751,955,000 from RMB 2,596,703,000 in the previous year[6] - Total liabilities increased to RMB 1,394,046,000 from RMB 1,299,848,000 in 2024[7] - Trade receivables increased to RMB 336,205,000 in 2025 from RMB 297,851,000 in 2024, an increase of 12.8%[31] - Trade payables rose to RMB 477,356,000 in 2025 from RMB 397,151,000 in 2024, an increase of 20.2%[33] - As of December 31, 2025, the current ratio was approximately 0.79, up from 0.39 on December 31, 2024, indicating improved liquidity[52] - The debt-to-asset ratio as of December 31, 2025, was 17.43%, down from 21.89% on December 31, 2024, reflecting a stronger capital structure[52] Cash Flow and Financing - The company reported a significant increase in cash and cash equivalents, rising to RMB 649,800,000 from RMB 116,884,000 in 2024[6] - The net financing cost decreased to RMB 14,021,000 in 2025 from RMB 8,927,000 in 2024, reflecting a reduction in interest income[22] - Net financing costs increased from RMB 3.1 million in the previous period to RMB 10.7 million, a rise of approximately 246.8%[47] - The net proceeds from the company's listing on December 22, 2025, amounted to approximately HKD 554.5 million, which will be used as disclosed in the prospectus[64] Employee and Operational Costs - Total salaries, wages, and other benefits rose to RMB 862,947,000 in 2025, up from RMB 817,185,000 in 2024, an increase of 5.6%[23] - Employee costs (excluding directors' remuneration) were approximately RMB 959.2 million, representing an increase of about RMB 52.6 million or 5.8% compared to the previous period[67] - Operating costs for the period were approximately RMB 2,294.3 million, an increase of about 5.4% year-on-year, primarily due to increased employee benefits expenses and depreciation from the second phase of Nanjing Mingji Hospital[44] - Depreciation and amortization expenses increased to RMB 192,111,000 in 2025 from RMB 168,690,000 in 2024, a rise of 13.9%[25] Revenue Sources and Growth - The company continues to focus on expanding its hospital services, with outpatient services generating RMB 1,254,183,000 and inpatient services generating RMB 1,433,987,000 in 2025[13] - In the reporting period, the revenue from inpatient medical services was RMB 1,434.0 million, an increase of 4.0% year-on-year; outpatient medical services revenue was RMB 1,254.2 million, an increase of 0.4% year-on-year[43] - Outpatient visits increased to approximately 2,171,253, while inpatient visits reached 87,276, both showing a year-on-year growth of 1.2%[38] - The average expenditure per inpatient visit rose to RMB 16,430 in 2025 from RMB 15,998 in 2024, indicating a 2.7% increase[39] - The bed occupancy rate improved to 98.9% in 2025, up from 97.1% in 2024, demonstrating enhanced operational efficiency[39] - The total number of registered beds increased from 1,850 in 2024 to 1,950 in 2025, supporting the growth in service capacity[39] Government and Regulatory Compliance - Government subsidies increased to RMB 2,832,000 in 2025 from RMB 1,554,000 in 2024, representing an increase of 82.5%[21] - The company has complied with all statutory social insurance and housing fund obligations applicable under Chinese law as of December 31, 2025[68] - The company has maintained a sufficient public float of at least 25% of its issued shares since the listing date, in accordance with listing rules[80] Corporate Governance and Future Plans - The company plans to expand its medical service capacity and strengthen specialty services in response to increasing healthcare demands in the Yangtze River Delta region[40] - The company aims to enhance multidisciplinary collaboration and specialty development to improve patient care and operational management[40] - The company plans to utilize the unspent net proceeds by December 31, 2026, for the purposes disclosed in the prospectus[66] - 74.3% of the net proceeds will be allocated for the expansion and upgrading of existing hospitals, totaling HKD 411.9 million[65] - 16.0% of the net proceeds, amounting to HKD 88.6 million, is earmarked for potential investment and acquisition opportunities by December 31, 2026[65] - The company plans to hold at least four board meetings annually, approximately quarterly, in compliance with corporate governance code C.5.1, starting from the fiscal year following its listing on December 22, 2025[75] - The audit committee, consisting of three members, will meet at least twice a year as per corporate governance code D.3.3, with the first meetings expected to occur in the fiscal year following the company's listing[77] - The annual general meeting is scheduled for June 5, 2026, with a share transfer registration suspension from May 29 to June 5, 2026, to determine shareholder voting eligibility[81] - The annual performance announcement will be published on the Hong Kong Stock Exchange and the company's website, with the annual report to follow in accordance with listing rules[82] Dividend and Shareholder Returns - The company did not declare any dividends for the fiscal year ending December 31, 2025, consistent with the previous year[35] - The company does not plan to declare a final dividend for the year ended December 31, 2025[70] - The company has not conducted any buybacks, sales, or redemptions of its listed securities from the listing date to the announcement date[72]
明基医院(02581) - 2025 - 年度业绩